Overview

Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia

Status:
Not yet recruiting

Trial end date:
2030-01-01

Target enrollment:

Participant gender:

Summary

GVHD remains a major cause of morbidity and mortality following SCT. The current standard of care for prophylaxis against GVHD includes tacrolimus and methotrexate. This study proposes to utilize acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, for GVHD prophylaxis following allogeneic SCT. The hypothesis is that the addition of acalabrutinib to our institutional standard GVHD prophylaxis (tacrolimus and methotrexate) is safe, feasible, and effective in reducing both the incidence and severity of acute GVHD.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Shin Mineishi

Collaborator:

Milton S. Hershey Medical Center

Treatments:

Acalabrutinib
Methotrexate
Tacrolimus